Physician profile
Peter J Weis
NPI 1639140296
$22,986.19
in general payments reported to CMS, 2019-2025
30 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,425 · 2020: $844 · 2021: $1,447 · 2022: $7,100 · 2023: $3,617 · 2024: $6,247 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,390 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,200 · Honoraria: $1,800 · Consulting Fee: $1,725 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,389.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,200.00 |
| Honoraria | $1,800.00 |
| Consulting Fee | $1,725.00 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $5,292.86 | 2019-2023 | Krystexxa |
| Abbvie INC. | $4,828.50 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $2,521.35 | 2019-2024 | Tremfya |
| Amgen INC. | $2,304.32 | 2019-2025 | Evenity, Krystexxa, Tavneos |
| Kyowa Kirin, INC. | $1,966.68 | 2024 | Crysvita |
| Astrazeneca Pharmaceuticals LP | $728.51 | 2022-2025 | Saphnelo |
| Pfizer INC. | $654.93 | 2019-2022 | |
| Genentech USA, INC. | $614.33 | 2019-2025 | Actemra |
| Novartis Pharmaceuticals Corporation | $555.98 | 2019-2025 | |
| Glaxosmithkline, LLC. | $522.67 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $502.24 | 2019-2025 | Taltz, Olumiant, Zepbound |
| Ucb, INC. | $339.88 | 2019-2025 | Bimzelx |
| Alexion Pharmaceuticals, INC. | $310.31 | 2019-2024 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.88 | 2020-2024 | Ofev |
| Aurinia Pharma U.S., INC. | $291.59 | 2021-2024 | Lupkynis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $234.88 | 2019-2021 | |
| Cardinal Health 110 LLC | $200.00 | 2021-2022 | |
| Pacira Therapeutics, INC. | $175.93 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $123.80 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $85.90 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $79.60 | 2020-2025 | Acthar |
| Sanofi-Aventis U.S. LLC | $76.44 | 2019-2020 | |
| Abbott Laboratories | $53.65 | 2022-2023 | Ensite |
| Actelion Pharmaceuticals US, INC. | $53.23 | 2019-2021 | |
| Depuy Synthes Sales INC. | $51.01 | 2023 | Orthovisc |
| Ferring Pharmaceuticals INC. | $43.81 | 2019 | |
| Celgene Corporation | $22.93 | 2019 | |
| Genzyme Corporation | $20.76 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $14.13 | 2022 | |
| Nevro Corp. | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Weis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.